Trial Profile
A Phase 2, Multicenter, Multinational, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of ORGN001 (Formerly ALXN1101) in Pediatric Patients With Molybdenum Cofactor Deficiency (MoCD) Type A Currently Treated With Recombinant Escherichia Coli-derived Cyclic Pyranopterin Monophosphate (rcPMP)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Fosdenopterin (Primary)
- Indications Molybdenum cofactor deficiency
- Focus Adverse reactions
- Sponsors Alexion AstraZeneca Rare Disease; Origin Biosciences
- 13 Oct 2022 Status changed from active, no longer recruiting to completed.
- 15 Nov 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 15 Nov 2021 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2022.